Physicians affiliated with US Oncology Research expand patient access to innovative cancer care by participating in the US Oncology Research program. We’re always searching for new practices who share this vision and passion for research to join US Oncology Research and expand the reach of novel therapies in their local communities.
US Oncology Research is one of the largest community-based research networks in America specializing in Phase I–IV oncology clinical trials. Our investigator-initiated and sponsor-initiated trials bring innovative therapies and clinical trials to practices and patients in local communities across the nation. Our trials have advanced treatments that reduce toxicities and offer the best benefits to patients.
What We Do Physicians are the drivers of US Oncology Research. It is led by a large number of key opinion leaders in oncology research. The size of our research program and the number of oncology experts associated with it allows for unparalleled access to industry-sponsored and investigator-initiated clinical trials. Through our comprehensive disease committee structure, we ensure that only the most promising trials are considered and conducted within US Oncology Research.
Translational Oncology Program Chaired by Daniel Von Hoff, MD — chief scientific officer with US Oncology Research and medical oncologist and physician-in-chief, senior investigator with Translational Genomics Research Institute (TGen) in Scottsdale, Arizona — the Translational Oncology Program (TOP) of The US Oncology Network is designed to address the special challenges of Phase I clinical trials, including increased safety concerns and more complex trial designs. TOP is a select group of physicians who have Phase I study experience, a dedicated staff, and facility equipment that meets the program’s criteria. We have 14 sites of care that provide Phase I clinical trials to patients, including first-in-human trials.
Through TOP, we take a leadership role in advancing new targeted cancer therapies. Our ability to deliver the latest therapies to patients as early as possible provides the best opportunity for successful treatment.